Zoetis (ZTS) Other Non-Current Assets (2012 - 2026)

Zoetis' (ZTS) quarterly Other Non-Current Assets came in at $351.0 million in Q1 2026, up 51.29% year-on-year from $232.0 million in Q1 2025, and up 7.34% on a QoQ basis from $327.0 million in Q4 2025.

Zoetis (ZTS) Other Non-Current Assets (2012 - 2026) Analysis & Trends

Zoetis (ZTS) has 15 years of Other Non-Current Assets data on file, last reported at $351.0 million in Q1 2026.

  • On a quarterly basis, Other Non-Current Assets rose 51.29% year-over-year to $351.0 million in Q1 2026; TTM through Mar 2026 was $351.0 million, a 51.29% increase from a year earlier, with the FY2025 full-year figure at $327.0 million, up 30.8% from the prior year.
  • Other Non-Current Assets for Q1 2026 stood at $351.0 million, up from $327.0 million in the prior quarter.
  • Over the last five years, Other Non-Current Assets for ZTS reached as high as $351.0 million in Q1 2026 and fell as low as $129.0 million in Q1 2022.
  • Historically, Other Non-Current Assets has averaged $224.1 million across 5 years, with a median of $216.0 million in 2023.
  • Across the five-year window, Other Non-Current Assets soared 88.44% in 2024 and retreated 18.1% in 2025, its largest moves.
  • Year by year, Other Non-Current Assets stood at $147.0 million in 2022, then soared by 40.14% to $206.0 million in 2023, then increased by 21.36% to $250.0 million in 2024, then surged by 30.8% to $327.0 million in 2025, then gained by 7.34% to $351.0 million in 2026.
  • Per Business Quant data, the three most recent Other Non-Current Assets figures were $351.0 million in Q1 2026, $327.0 million in Q4 2025, and $293.0 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Other Non-Current Assets (Qtr)
1 Haleon 88.07 Bn 86.20 Bn - 49.22 Mn
2 Teva Pharmaceutical Industries 35.75 Bn 32.01 Bn 1.97 Bn 377.00 Mn
3 Zoetis 31.84 Bn 29.90 Bn 1.62 Bn 351.00 Mn
4 Takeda Pharmaceutical 27.18 Bn 23.12 Bn 4.39 Bn 491.06 Mn
5 United Therapeutics 23.09 Bn 20.93 Bn 648.10 Mn 233.20 Mn
6 RedHill Biopharma 21.32 Bn 21.32 Bn - 169,000.00
7 Viatris 19.96 Bn 18.16 Bn 1.16 Bn 1.11 Bn
8 Neurocrine Biosciences 17.66 Bn 16.34 Bn 800.70 Mn 73.60 Mn
9 Elanco Animal Health 12.44 Bn 12.02 Bn 785.00 Mn 295.00 Mn
10 Vireo Growth 10.53 Bn 10.38 Bn 59.30 Mn 4.40 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 351.00 Mn
Dec 31, 2025 327.00 Mn
Sep 30, 2025 293.00 Mn
Jun 30, 2025 267.00 Mn
Mar 31, 2025 232.00 Mn
Dec 31, 2024 250.00 Mn
Sep 30, 2024 215.00 Mn
Jun 30, 2024 326.00 Mn
Mar 31, 2024 227.00 Mn
Dec 31, 2023 206.00 Mn
Sep 30, 2023 216.00 Mn
Jun 30, 2023 173.00 Mn
Mar 31, 2023 143.00 Mn
Dec 31, 2022 147.00 Mn
Sep 30, 2022 161.00 Mn
Jun 30, 2022 147.00 Mn
Mar 31, 2022 129.00 Mn
Dec 31, 2021 111.00 Mn
Sep 30, 2021 112.00 Mn
Jun 30, 2021 97.00 Mn